SILVER SPRING, Md., July 30, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix products, today announced that it will release its second quarter 2024 financial results after market close on Wednesday, August 7, 2024. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID: 13747696 Please log in approximately 10 minutes prior to the scheduled start time. A l
DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies."During the second quarter we advanced capital to two existing borrowers and are working towards an additional closing in the next month," said SWK President and CEO Jody Staggs."Importantly, several of our borrower partners took advantage of the strong capital markets to raise equity or other forms of non-dilutive financing. We also repurchased $1 million of st
SILVER SPRING, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a company pioneering drug-eluting biomatrix products, today provided a business update and financial results for the first quarter ended March 31, 2024. Business Highlights: Generated strong revenue growth for proprietary product lines in the first quarter of 2024, led by SimpliDerm net sales increasing 55% compared to the first quarter of 2023FDA interactions regarding CanGarooRM, Elutia's antibiotic-eluting biologic envelope, continue to be positiveAddressing the final details for CanGarooRM clearance; anticipate FDA decision in the second quarter of 2024Preparing for launch of C
Company Thanks Stakeholders and Employees for a Year of Remarkable Growth and Accomplishment SILVER SPRING, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a pioneer in drug-eluting biomatrix products, is celebrating its one-year anniversary and the team that made it possible. On September 6, 2023, as part of a strategic shift toward drug-eluting biologics, the company rebranded as Elutia Inc. and established the mission of "Humanizing Medicine so Patients can Thrive without Compromise." The following day, the company began trading on Nasdaq under the new ticker symbol "ELUT." In its first year as Elutia, the company achieved several significant milestones a
SILVER SPRING, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a pioneer in drug-eluting biomatrix products, today announced a landmark achievement with the first-ever patient implant of EluPro®, the world's first antibiotic-eluting biologic envelope cleared by the U.S. Food and Drug Administration (FDA). The groundbreaking procedure was performed by John Catanzaro, MD, MBA, Chief, Division of Cardiology, Director, Cardiology Services, and Program Director of Clinical Cardiac Electrophysiology Fellowship at East Carolina University Health Medical Center in Greenville, North Carolina. "We are honored to be the first facility to implant EluPro," said Dr. Cata
SILVER SPRING, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a pioneer in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will participate in the following upcoming investor conferences in New York: H.C. Wainwright 26th Annual Global Investment ConferenceFormat: Presentation and 1x1 MeetingsPresentation Date and Time (On-demand beginning): Monday, September 9, 2024, 7:00 a.m. ET 1x1 Meetings: Wednesday, September 11, 2024Webcast: Click here Lake Street Capital Markets 8th Annual Best Ideas Growth ConferenceFormat: 1x1 MeetingsDate: Thursday, September
Lake Street analyst Frank Takkinen maintains Elutia (NASDAQ:ELUT) with a Buy and raises the price target from $5 to $10.
Cantor Fitzgerald analyst Ross Osborn maintains Elutia (NASDAQ:ELUT) with a Overweight and raises the price target from $5 to $11.
Cantor Fitzgerald analyst Ross Osborn maintains Elutia (NASDAQ:ELUT) with a Overweight and raises the price target from $5 to $11.
4/A - ELUTIA INC. (0001708527) (Issuer)
10-Q - ELUTIA INC. (0001708527) (Filer)
8-K - ELUTIA INC. (0001708527) (Filer)
8-K - ELUTIA INC. (0001708527) (Filer)
4 - ELUTIA INC. (0001708527) (Issuer)
4 - ELUTIA INC. (0001708527) (Issuer)
4 - ELUTIA INC. (0001708527) (Issuer)
SC 13G/A - ELUTIA INC. (0001708527) (Subject)
SILVER SPRING, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a pioneer in drug-eluting biomatrix products, today announced the appointment of Ryan Marques, Ph.D, MBA as Vice President of Operations. Dr. Marques brings more than 20 years of experience leading operations teams across manufacturing, quality assurance, supply chain and technical services in the device and pharmaceutical industries. "We are pleased to welcome Ryan to the Elutia CRU as our new Vice President of Operations," said Dr. Randy Mills, Elutia's Chief Executive Officer. "At Elutia, culture matters, and Ryan has both the experience and character to make him an excellent fit and an effectiv